imipramine has been researched along with Agoraphobia in 143 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse." | 9.10 | Duration of imipramine therapy and relapse in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2002) |
| "In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2." | 9.10 | Specific side effects of long-term imipramine management of panic disorder. ( Guo, S; Mavissakalian, M; Perel, J, 2002) |
| "The results from our 1 year placebo-controlled maintenance/discontinuation study in remitted panic disorder with agoraphobia patients confirmed the significant prophylactic effectiveness of imipramine maintenance treatment but suggested that this may be necessary in only 37% of the patients who relapse following discontinuation of 6 months acute imipramine treatment." | 9.09 | 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2001) |
| " The aim of the present study was to assess the 12-month cumulative risk of relapse specifically due to discontinuation of imipramine and to test the hypothesis that maintenance treatment with imipramine protects patients with panic disorder and agoraphobia from such reversals." | 9.09 | Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 1999) |
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 9.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| "Eighty patients with panic disorder with agoraphobia were randomly assigned, for an 8-week, double-blind dose-ranging trial, to placebo or to a weight-adjusted dose of imipramine: (low) 0." | 9.08 | Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. ( Mavissakalian, MR; Perel, JM, 1995) |
| "This study compared the efficacy, tolerability, and safety of fluvoxamine, imipramine, and placebo in the treatment of panic disorder with or without agoraphobia." | 9.08 | A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. ( Bakish, D; Charbonneau, Y; Filteau, MJ; Fraser, G; Hooper, CL; Raine, D; Thibaudeau, C; West, DL, 1996) |
| "This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol." | 9.07 | Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm. ( de Groot, CM; Mavissakalian, MR, 1994) |
| "This study was designed to assess and compare the differential relapse rates of patients with panic disorder and agoraphobia after discontinuation of acute treatment (6 months) or acute plus maintenance treatment (18 months) with imipramine." | 9.07 | Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 9.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "Several issues remain to be ascertained beyond the acute response to imipramine hydrochloride in patients with panic disorder." | 9.07 | Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "This naturalistic study examined the treatment response to imipramine of 60 patients who had panic disorder or agoraphobia with panic attacks." | 9.06 | A naturalistic study of imipramine in panic disorder and agoraphobia. ( Aronson, TA, 1987) |
| "Thirty-seven patients participating in a controlled treatment study with imipramine were classified as high or low depressed simultaneously on two depression measures." | 9.06 | Initial depression and response to imipramine in agoraphobia. ( Mavissakalian, M, 1987) |
| "A double-blind clinical trial of zimeldine, a potent inhibitor of central serotonin reuptake, versus imipramine and placebo was carried out on 44 patients suffering from agoraphobia with panic attacks." | 9.06 | Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. ( Evans, L; Hoey, H; Kenardy, J; Schneider, P, 1986) |
| "At the end of a two-week single-blind placebo baseline, 43 patients with a diagnosis of panic disorder with agoraphobia without significant dysphoria-depression and with moderate to severe panic and phobic symptoms were assigned to, and 32 of them completed, a placebo-controlled (n = 7) dose-response study with three weight-adjusted imipramine hydrochloride dosages: 0." | 9.06 | Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. ( Mavissakalian, MR; Perel, JM, 1989) |
| "This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine." | 7.77 | Imipramine for vestibular dysfunction in panic disorder: a prospective case series. ( Mathias, Kde V; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM, 2011) |
| "One hundred and ten consecutive patients with DSM-III-R moderate to severe panic disorder with agoraphobia were treated with a fixed regimen of imipramine 2." | 7.70 | Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 7.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "Thirty-eight patients who had panic disorder with agoraphobia completed 8 weeks of treatment with imipramine followed by 8 weeks of treatment with imipramine combined with behavior therapy consisting of self-directed exposure." | 7.68 | Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. ( Mavissakalian, M, 1990) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 7.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged." | 7.68 | Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. ( Charney, DS; Krystal, JH; Merikangas, KR; Nagy, LM; Woods, SW, 1993) |
| " We studied the binding of tritiated imipramine to platelet membranes in order to determine if patients with agoraphobia and panic attacks differed from depressed subjects or healthy volunteers on this biological parameter." | 7.67 | Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. ( Clancy, J; Coryell, W; Lewis, DA; Noyes, R, 1985) |
| " These treatments were combined with imipramine or placebo for a total of eight experimental conditions." | 6.73 | Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. ( Borgeat, F; Coutu, MF; Dupuis, G; Fleet, R; Mainguy, N; Marchand, A; Todorov, C, 2008) |
| "Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings." | 6.69 | Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. ( Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 6.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "The authors examined dose-response relationships in 62 agoraphobic patients receiving either imipramine or placebo under double-blind conditions in conjunction with behavioral interventions." | 6.66 | Imipramine in the treatment of agoraphobia: dose-response relationships. ( Mavissakalian, M; Perel, J, 1985) |
| "The authors explored the prognostic value of 3 different types of catastrophic cognitions in the treatment of panic disorder with and without mild-to-moderate agoraphobia using a sample of 143 participants who received either cognitive-behavioral therapy (CBT) or imipramine in a randomized controlled trial." | 5.11 | Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. ( Barlow, DH; Gorman, JM; Hicks, TV; Leitenberg, H; Shear, MK; Woods, SW, 2005) |
| "It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse." | 5.10 | Duration of imipramine therapy and relapse in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2002) |
| "In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2." | 5.10 | Specific side effects of long-term imipramine management of panic disorder. ( Guo, S; Mavissakalian, M; Perel, J, 2002) |
| "The results from our 1 year placebo-controlled maintenance/discontinuation study in remitted panic disorder with agoraphobia patients confirmed the significant prophylactic effectiveness of imipramine maintenance treatment but suggested that this may be necessary in only 37% of the patients who relapse following discontinuation of 6 months acute imipramine treatment." | 5.09 | 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2001) |
| " The aim of the present study was to assess the 12-month cumulative risk of relapse specifically due to discontinuation of imipramine and to test the hypothesis that maintenance treatment with imipramine protects patients with panic disorder and agoraphobia from such reversals." | 5.09 | Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 1999) |
| " Thirty-seven outpatients with panic disorder and agoraphobia (PDA) were treated with imipramine (75-150 mg/day) in an 8-week open, prospective trial." | 5.09 | Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. ( Bandelow, B; Beinroth, D; Broocks, A; Brunner, E; Hajak, G; Pralle, L; Rüther, E, 1999) |
| "Emotion-focused psychotherapy was less effective for symptoms of panic disorder than treatment with either cognitive behavior therapy or imipramine; results obtained with emotion-focused psychotherapy after the acute and maintenance phases were similar to those seen with placebo." | 5.09 | Emotion-focused psychotherapy for patients with panic disorder. ( Greeno, C; Houck, P; Masters, S; Shear, MK, 2001) |
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 5.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| "This study compared the efficacy, tolerability, and safety of fluvoxamine, imipramine, and placebo in the treatment of panic disorder with or without agoraphobia." | 5.08 | A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. ( Bakish, D; Charbonneau, Y; Filteau, MJ; Fraser, G; Hooper, CL; Raine, D; Thibaudeau, C; West, DL, 1996) |
| "Forty-seven patients meeting DSM-III-R criteria for panic disorder with agoraphobia (PAG) were assessed by the Minnesota Multiphasic Personality Inventory (MMPI) at baseline and after 8 weeks of treatment with imipramine, clomipramine and placebo." | 5.08 | Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. ( Gentil, V; Gorenstein, C; Ito, LM; Miyakawa, E, 1995) |
| "50 patients with panic disorder (30 without and 20 with concomitant depression) were enrolled in a controlled treatment study using either imipramine or doxepin in addition to supportive psychotherapy and were then studied under naturalistic treatment conditions over a 5-year period." | 5.08 | Panic disorder with or without concomitant depression 5 years after treatment: a prospective follow-up. ( Albus, M; Scheibe, G; Scherer, J, 1995) |
| "Eighty patients with panic disorder with agoraphobia were randomly assigned, for an 8-week, double-blind dose-ranging trial, to placebo or to a weight-adjusted dose of imipramine: (low) 0." | 5.08 | Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. ( Mavissakalian, MR; Perel, JM, 1995) |
| "After controlled treatment with either imipramine or doxepin with additional psychotherapy, 30 patients with pure panic disorder and 20 with concomitant depression were followed under ordinary treatment conditions over a 5-year period." | 5.08 | Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up. ( Albus, M; Scheibe, G; Scherer, J, 1995) |
| " The present study provided systematic data from a double blind comparison of maintenance therapy (up to 8 months) of panic disorder with or without agoraphobia with alprazolam, imipramine, or placebo in 181 patients who had responded to the same regimen in a randomized 8-week treatment trial." | 5.07 | Maintenance drug therapy of panic disorder. ( Ayuso, JL; Cassano, GB; Curtis, GC; Massana, J; Perugi, G; Udina, C, 1993) |
| "The impact of the avoidance behaviour on the psychopharmacological treatment of panic disorder was explored in the Cross National Collaborative Panic Study (n = 1134 patients); in this double blind randomized trial alprazolam, imipramine and placebo were compared during an 8-week treatment period." | 5.07 | Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? ( Argyle, N; Benkert, O; Brandon, S; Buller, R; Lavori, P; Maier, W; Roth, SM, 1991) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 5.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol." | 5.07 | Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm. ( de Groot, CM; Mavissakalian, MR, 1994) |
| "Several issues remain to be ascertained beyond the acute response to imipramine hydrochloride in patients with panic disorder." | 5.07 | Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "This study was designed to assess and compare the differential relapse rates of patients with panic disorder and agoraphobia after discontinuation of acute treatment (6 months) or acute plus maintenance treatment (18 months) with imipramine." | 5.07 | Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "A double-blind clinical trial of zimeldine, a potent inhibitor of central serotonin reuptake, versus imipramine and placebo was carried out on 44 patients suffering from agoraphobia with panic attacks." | 5.06 | Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. ( Evans, L; Hoey, H; Kenardy, J; Schneider, P, 1986) |
| "This naturalistic study examined the treatment response to imipramine of 60 patients who had panic disorder or agoraphobia with panic attacks." | 5.06 | A naturalistic study of imipramine in panic disorder and agoraphobia. ( Aronson, TA, 1987) |
| "Thirty-seven patients participating in a controlled treatment study with imipramine were classified as high or low depressed simultaneously on two depression measures." | 5.06 | Initial depression and response to imipramine in agoraphobia. ( Mavissakalian, M, 1987) |
| "At the end of a two-week single-blind placebo baseline, 43 patients with a diagnosis of panic disorder with agoraphobia without significant dysphoria-depression and with moderate to severe panic and phobic symptoms were assigned to, and 32 of them completed, a placebo-controlled (n = 7) dose-response study with three weight-adjusted imipramine hydrochloride dosages: 0." | 5.06 | Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. ( Mavissakalian, MR; Perel, JM, 1989) |
| "The recognition of the efficacy of imipramine for treating panic disorder and its complications has had major implications for clinical practice, diagnostic classification, theoretic understanding, and research strategies in the anxiety disorders." | 5.05 | Imipramine in the treatment of panic disorder and its complications. ( Liebowitz, MR, 1985) |
| " In this paper, we selectively review the author's research with the standard antidepressant, imipramine, in the treatment of panic disorder with agoraphobia as it relates to practical issues." | 4.80 | Rational treatment of panic disorder with antidepressants. ( Mavissakalian, MR; Ryan, MT, 1998) |
| " Many double-blind controlled studies have shown that imipramine effectively ameliorates panic attacks and agoraphobia." | 4.77 | Panic disorder: response to sodium lactate and treatment with antidepressants. ( Rifkin, A; Siris, SG, 1985) |
| " Among the more important recent discoveries are the efficacy of the tricyclic antidepressants for panic disorder and agoraphobia with panic attacks; the use of the monoamine oxidase inhibitors for the above disorders and for atypical depression and hysteroid dysphoria; the use of propranolol for anxiety disorders and for uncontrollable violent outbursts; the antianxiety and antipanic effects of clonidine; and the usefulness of lithium in treating schizophrenia and schizoaffective disorder and for emotionally unstable character disorders." | 4.76 | Newer uses for older psychotropic medications. ( Liebowitz, MR, 1982) |
| "This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine." | 3.77 | Imipramine for vestibular dysfunction in panic disorder: a prospective case series. ( Mathias, Kde V; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM, 2011) |
| "The psychopharmacological treatment of separation anxiety is reviewed, with special emphasis on the use of tricyclic antidepressants." | 3.75 | Relationship between separation anxiety and panic and agoraphobic disorders. ( Gittelman, R; Klein, DF, 1984) |
| "One hundred and ten consecutive patients with DSM-III-R moderate to severe panic disorder with agoraphobia were treated with a fixed regimen of imipramine 2." | 3.70 | Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998) |
| " In this naturalistic study, 49 patients affected by panic disorder with agoraphobia (n = 36) or without agoraphobia (n = 13) were treated with IMI plus lorazepam (LRZ) and followed for 12 months." | 3.69 | The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. ( Ampollini, P; Maggini, C; Marchesi, C; Signifredi, R, 1997) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 3.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "Thirty-eight patients who had panic disorder with agoraphobia completed 8 weeks of treatment with imipramine followed by 8 weeks of treatment with imipramine combined with behavior therapy consisting of self-directed exposure." | 3.68 | Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. ( Mavissakalian, M, 1990) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 3.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged." | 3.68 | Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. ( Charney, DS; Krystal, JH; Merikangas, KR; Nagy, LM; Woods, SW, 1993) |
| " Imipramine hydrochloride, which has complex effects on noradrenergic function in animals, is effective in patients with agoraphobia and panic disorder." | 3.67 | Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. ( Charney, DS; Heninger, GR, 1985) |
| " We studied the binding of tritiated imipramine to platelet membranes in order to determine if patients with agoraphobia and panic attacks differed from depressed subjects or healthy volunteers on this biological parameter." | 3.67 | Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. ( Clancy, J; Coryell, W; Lewis, DA; Noyes, R, 1985) |
| "This study was designed to see whether the high vs low serum level of imipramine influenced the outcome of in vivo exposure therapy on patients with agoraphobia." | 3.67 | Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. ( Ballenger, JC; Cox, DJ; Hobbs, WR; Hucek, A; Laraia, M; Peterson, GA, 1988) |
| "3H-Imipramine (3H-IMI) binding to platelet membranes was measured in 19 patients with agoraphobia with panic attacks, 9 patients with major depression, and 22 healthy subjects." | 3.67 | Differential 3H-imipramine platelet binding in patients with panic disorder and depression. ( Charney, DS; Heninger, GR; Innis, RB, 1987) |
| "Ten cases are presented--two in detail--in which clonazepam was used successfully in patients with treatment-resistant panic disorder with or without agoraphobia." | 3.67 | Successful use of clonazepam in patients with treatment-resistant panic disorder. ( Rosenbaum, JF; Tesar, GE, 1986) |
| "Reports that imipramine and phenelzine prevent panic attacks in agoraphobia suggest the possibility that agoraphobia and/or panic disorder might be a clinical manifestation of underlying depression." | 3.66 | The dexamethasone suppression test in panic disorder and agoraphobia. ( Cameron, OG; Curtis, GC; Nesse, RM, 1982) |
| " These treatments were combined with imipramine or placebo for a total of eight experimental conditions." | 2.73 | Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. ( Borgeat, F; Coutu, MF; Dupuis, G; Fleet, R; Mainguy, N; Marchand, A; Todorov, C, 2008) |
| "Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings." | 2.69 | Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. ( Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999) |
| "Buspirone was compared with imipramine and placebo in the treatment of panic disorder in an 8-week, double-blind controlled study of 52 randomly assigned patients." | 2.67 | Is buspirone effective for panic disorder? ( Raj, AB; Sheehan, DV; Sheehan, KH; Soto, S, 1990) |
| "The alprazolam effects were apparent by week 1; the imipramine effects by week 4." | 2.67 | Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. ( Agras, WS; Clark, D; Ehlers, A; Hayward, C; King, R; Maddock, R; Margraf, J; Roth, WT; Taylor, CB, 1990) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 2.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "Imipramine was superior to placebo in lowering panic and avoidance at both postbaseline time points." | 2.66 | Panic and avoidance in agoraphobia. Application of path analysis to treatment studies. ( Cohen, P; Klein, DF; Ross, DC, 1987) |
| "The authors examined dose-response relationships in 62 agoraphobic patients receiving either imipramine or placebo under double-blind conditions in conjunction with behavioral interventions." | 2.66 | Imipramine in the treatment of agoraphobia: dose-response relationships. ( Mavissakalian, M; Perel, J, 1985) |
| "Brief therapist-aided exposure improved phobias and panics to a significant but limited extent, and is a useful adjuvant to self-exposure homework, which can be a powerful therapeutic agency by itself." | 2.65 | Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework. ( Cohen, D; Gray, S; Hill, R; Marks, IM; Mawson, D; Ramm, E; Stern, RS, 1983) |
| "In a controlled-outcome study of phobias, 218 adult phobic patients (147 women and 71 men) received a course of 26 weekly treatment sessions that consisted of behavior therapy (BT) and imipramine hydrochloride, BT and placebo, or supportive psychotherapy and imipramine." | 2.65 | Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. ( Klein, DF; Ross, DC; Woerner, MG; Zitrin, CM, 1983) |
| "In a controlled outcome study of phobias, 111 adult patients (69% women, 31% men) received a course of 26 weekly treatment sessions consisting of (1) behavior therapy and imipramine hydrochloride (2) behavior therapy and placebo, or (3) supportive psychotherapy and imipramine." | 2.64 | Behavior therapy, supportive psychotherapy, imipramine, and phobias. ( Klein, DF; Woerner, MG; Zitrin, CM, 1978) |
| "Panic disorder is characterised by recurrent unexpected panic attacks consisting of a wave of intense fear that reaches a peak within a few minutes." | 2.61 | Benzodiazepines versus placebo for panic disorder in adults. ( Barbui, C; Bighelli, I; Breilmann, J; Castellazzi, M; Cipriani, A; Davies, SJ; Furukawa, TA; Girlanda, F; Guaiana, G; Koesters, M, 2019) |
| "Posttraumatic stress disorder (PTSD) is frequently associated with major depressive disorder, and antidepressants have been reported to ameliorate PTSD symptoms in some patients." | 1.29 | Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment. ( Abramovitz-Schnaider, P; Freudstein-Dan, A; Laor, N; Rehavi, M; Schujovitsky, A; Weizman, R; Wolmer, L, 1996) |
| "A review of the literature on treatments for agoraphobia highlights the conclusion reached, that the agoraphobic patient presents with a biopsychosocial problem which frequently requires the clinician to combine several treatment modalities." | 1.27 | Agoraphobia: a multimodal treatment approach. ( Schwartz, LS; Val, ER, 1984) |
| "The hallmark of agoraphobia is the spontaneous panic attack, a reaction of extreme fearfulness and impending doom with cardiorespiratory symptoms." | 1.26 | Current drug therapy for agoraphobia. ( Ravaris, CL, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (60.14) | 18.7374 |
| 1990's | 43 (30.07) | 18.2507 |
| 2000's | 12 (8.39) | 29.6817 |
| 2010's | 2 (1.40) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breilmann, J | 1 |
| Girlanda, F | 1 |
| Guaiana, G | 1 |
| Barbui, C | 1 |
| Cipriani, A | 1 |
| Castellazzi, M | 1 |
| Bighelli, I | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 2 |
| Koesters, M | 1 |
| Marchand, A | 1 |
| Coutu, MF | 1 |
| Dupuis, G | 1 |
| Fleet, R | 1 |
| Borgeat, F | 1 |
| Todorov, C | 1 |
| Mainguy, N | 1 |
| Raffa, SD | 1 |
| Stoddard, JA | 1 |
| White, KS | 1 |
| Barlow, DH | 4 |
| Gorman, JM | 7 |
| Shear, MK | 3 |
| Woods, SW | 6 |
| Katherine Shear, M | 1 |
| Money, R | 1 |
| Etschel, E | 1 |
| Engel, RR | 1 |
| Leucht, S | 1 |
| Mezzasalma, MA | 1 |
| Mathias, Kde V | 1 |
| Nascimento, I | 1 |
| Valença, AM | 1 |
| Nardi, AE | 1 |
| Mavissakalian, MR | 9 |
| Perel, JM | 10 |
| Andersch, S | 1 |
| Hetta, J | 1 |
| Hicks, TV | 1 |
| Leitenberg, H | 1 |
| Uhlenhuth, EH | 2 |
| Leon, AC | 1 |
| Matuzas, W | 2 |
| Zitrin, CM | 9 |
| Klein, DF | 15 |
| Woerner, MG | 5 |
| Liebowitz, MR | 6 |
| Ross, DC | 3 |
| Marks, IM | 3 |
| Gray, S | 1 |
| Cohen, D | 1 |
| Hill, R | 1 |
| Mawson, D | 1 |
| Ramm, E | 1 |
| Stern, RS | 1 |
| Telch, MJ | 3 |
| Tearnan, BH | 1 |
| Taylor, CB | 4 |
| Cobb, J | 1 |
| Zelnik, TC | 1 |
| Garcia-Sevilla, JA | 1 |
| Cameron, OG | 2 |
| Smith, CB | 1 |
| Garakani, H | 1 |
| Cohen, SD | 1 |
| Monteiro, W | 1 |
| Pohl, R | 5 |
| Rainey, JM | 2 |
| Gershon, S | 2 |
| Gittelman, R | 1 |
| Boulenger, JP | 1 |
| Uhde, TW | 1 |
| Michelson, L | 8 |
| Mavissakalian, M | 19 |
| Meminger, S | 1 |
| Dealy, RS | 1 |
| Last, CG | 1 |
| O'Brien, GT | 1 |
| Schwartz, LS | 1 |
| Val, ER | 1 |
| Perel, J | 3 |
| Fyer, AJ | 4 |
| Dillon, D | 2 |
| Appleby, IL | 1 |
| Levy, G | 1 |
| Anderson, S | 1 |
| Levitt, M | 1 |
| Palij, M | 1 |
| Davies, SO | 2 |
| Glass, RM | 1 |
| Fier, M | 1 |
| Davis, JM | 1 |
| Nasr, S | 1 |
| Spira, N | 1 |
| Vogel, C | 1 |
| Sheehan, DV | 3 |
| Curtis, GC | 2 |
| Nesse, RM | 1 |
| Shrand, H | 1 |
| Berchou, R | 1 |
| Ravaris, CL | 1 |
| Albus, M | 4 |
| Scheibe, G | 3 |
| Scherer, J | 2 |
| Boerner, RJ | 2 |
| Pecknold, JC | 2 |
| Luthe, L | 1 |
| Iny, L | 1 |
| Ramdoyal, D | 1 |
| Nagy, LM | 1 |
| Krystal, JH | 1 |
| Charney, DS | 5 |
| Merikangas, KR | 1 |
| Massana, J | 1 |
| Udina, C | 1 |
| Ayuso, JL | 1 |
| Cassano, GB | 2 |
| Perugi, G | 2 |
| de Groot, CM | 1 |
| Lepola, UM | 1 |
| Rimón, RH | 1 |
| Riekkinen, PJ | 1 |
| Schweizer, E | 1 |
| Rickels, K | 2 |
| Weiss, S | 1 |
| Zavodnick, S | 1 |
| Balon, R | 3 |
| Yeragani, VK | 3 |
| Merlos, B | 2 |
| Sherwood, P | 1 |
| Ito, LM | 1 |
| Gorenstein, C | 1 |
| Gentil, V | 1 |
| Miyakawa, E | 1 |
| Weizman, R | 1 |
| Laor, N | 1 |
| Schujovitsky, A | 1 |
| Wolmer, L | 1 |
| Abramovitz-Schnaider, P | 1 |
| Freudstein-Dan, A | 1 |
| Rehavi, M | 1 |
| Rosenbaum, JF | 2 |
| Pollack, MH | 1 |
| Pollock, RA | 1 |
| Bakish, D | 1 |
| Hooper, CL | 1 |
| Filteau, MJ | 1 |
| Charbonneau, Y | 1 |
| Fraser, G | 1 |
| West, DL | 1 |
| Thibaudeau, C | 1 |
| Raine, D | 1 |
| Milrod, B | 1 |
| Busch, F | 1 |
| Marchesi, C | 1 |
| Ampollini, P | 1 |
| Signifredi, R | 1 |
| Maggini, C | 1 |
| Talbott-Green, M | 1 |
| Sloan, C | 1 |
| Gurguis, GN | 1 |
| Antai-Otong, D | 1 |
| Vo, SP | 1 |
| Blakeley, JE | 1 |
| Orsulak, PJ | 1 |
| Petty, F | 1 |
| Rush, AJ | 1 |
| Ryan, MT | 1 |
| Bandelow, B | 2 |
| Brunner, E | 2 |
| Beinroth, D | 2 |
| Pralle, L | 2 |
| Broocks, A | 2 |
| Hajak, G | 2 |
| Rüther, E | 2 |
| Rupprecht, R | 1 |
| Ströhle, A | 1 |
| Toni, C | 2 |
| Frare, F | 1 |
| Mata, B | 1 |
| Vitale, B | 1 |
| Mengali, F | 1 |
| Recchia, M | 1 |
| Serra, G | 1 |
| Akiskal, HS | 1 |
| Houck, P | 1 |
| Greeno, C | 1 |
| Masters, S | 1 |
| Guo, S | 1 |
| Lindemann, C | 1 |
| Tobak, P | 1 |
| Rock, M | 1 |
| Kaplan, JE | 1 |
| Ganz, VH | 1 |
| Ramesh, C | 1 |
| Glitz, D | 1 |
| Weinberg, P | 1 |
| Cox, BJ | 2 |
| Endler, NS | 2 |
| Lee, PS | 1 |
| Swinson, RP | 2 |
| Musetti, L | 1 |
| Maier, W | 3 |
| Roth, SM | 1 |
| Argyle, N | 3 |
| Buller, R | 3 |
| Lavori, P | 1 |
| Brandon, S | 2 |
| Benkert, O | 2 |
| Rosenberg, R | 2 |
| Roth, M | 1 |
| Westberg, P | 1 |
| Modigh, K | 1 |
| Lisjö, P | 1 |
| Eriksson, E | 1 |
| Solyom, C | 1 |
| Solyom, L | 1 |
| Mattick, RP | 1 |
| Andrews, G | 1 |
| Hadzi-Pavlovic, D | 1 |
| Christensen, H | 1 |
| Delgado, PL | 1 |
| Heninger, GR | 4 |
| Hayward, C | 1 |
| King, R | 1 |
| Ehlers, A | 1 |
| Margraf, J | 1 |
| Maddock, R | 1 |
| Clark, D | 1 |
| Roth, WT | 3 |
| Agras, WS | 3 |
| Lecrubier, Y | 1 |
| Hippius, H | 1 |
| Raj, AB | 1 |
| Sheehan, KH | 1 |
| Soto, S | 1 |
| Lepola, U | 1 |
| Jolkkonen, J | 1 |
| Rimón, R | 1 |
| Riekkinen, P | 1 |
| Noyes, R | 3 |
| Garvey, MJ | 1 |
| Cook, BL | 1 |
| Samuelson, L | 1 |
| Ballenger, JC | 2 |
| Carek, DJ | 1 |
| Steele, JJ | 1 |
| Cornish-McTighe, D | 1 |
| Brady, K | 1 |
| Zarzar, M | 1 |
| Lydiard, RB | 1 |
| Gallen, CC | 1 |
| Rizley, R | 1 |
| Kahn, RJ | 2 |
| McNair, DM | 2 |
| Frankenthaler, LM | 2 |
| Cohen, P | 1 |
| Scott, WB | 1 |
| Fleming, BM | 1 |
| Kritkausky, RP | 1 |
| Lelliott, P | 1 |
| Marks, I | 2 |
| Evans, L | 1 |
| Kenardy, J | 1 |
| Schneider, P | 1 |
| Hoey, H | 1 |
| Lewis, DA | 1 |
| Coryell, W | 1 |
| Clancy, J | 1 |
| Innis, RB | 1 |
| Davis, DM | 1 |
| O'Sullivan, G | 1 |
| Cox, DJ | 1 |
| Laraia, M | 1 |
| Hobbs, WR | 1 |
| Peterson, GA | 1 |
| Hucek, A | 1 |
| Klerman, GL | 1 |
| Aronson, TA | 1 |
| Lelliott, PT | 1 |
| Monteiro, WO | 1 |
| Tsakiris, F | 1 |
| Noshirvani, H | 1 |
| Cohen, BS | 1 |
| Lipman, RS | 1 |
| Covi, L | 1 |
| Downing, R | 1 |
| Fisher, S | 1 |
| Surman, OS | 1 |
| Williams, J | 1 |
| Strom, TB | 1 |
| Jones, KJ | 1 |
| Coleman, J | 1 |
| Goodman, WK | 1 |
| Rifkin, B | 1 |
| Kinch, M | 1 |
| Aiken, B | 1 |
| Quadrino, LM | 1 |
| Robinson, ML | 1 |
| Jones, A | 1 |
| Crowe, RR | 1 |
| Ambrosini, P | 1 |
| Tesar, GE | 1 |
| Schneider, LS | 1 |
| Munjack, D | 1 |
| Severson, JA | 1 |
| Palmer, R | 1 |
| Rifkin, A | 1 |
| Siris, SG | 1 |
| Stewart, JT | 1 |
| Lawlor, BA | 1 |
20 reviews available for imipramine and Agoraphobia
| Article | Year |
|---|---|
Benzodiazepines versus placebo for panic disorder in adults.
Topics: Adult; Aged; Agoraphobia; Benzodiazepines; Buspirone; Humans; Imipramine; Middle Aged; Numbers Neede | 2019 |
Newer uses for older psychotropic medications.
Topics: Adrenergic beta-Antagonists; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Clonidine; Depressive | 1982 |
Antidepressant medication in the treatment of agoraphobia: a critical review.
Topics: Agoraphobia; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior Therapy; Clomipramine | 1983 |
Behaviour therapy in phobic and obsessional disorders.
Topics: Agoraphobia; Arousal; Behavior Therapy; Clomipramine; Cognition; Combined Modality Therapy; Desensit | 1983 |
Changes in the drug treatment of anxiety disorders.
Topics: Agoraphobia; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder | 1984 |
Relationship between separation anxiety and panic and agoraphobic disorders.
Topics: Adult; Agoraphobia; Anxiety Disorders; Anxiety, Separation; Child; Clinical Trials as Topic; Fear; F | 1984 |
[Treatment of panic attacks].
Topics: Agoraphobia; Antidepressive Agents; Combined Modality Therapy; Fear; Humans; Imipramine; Mental Diso | 1983 |
Current concepts in psychiatry. Panic attacks and phobias.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents; Anxiety Disorders; Behavior Therapy; Clinical | 1982 |
Combined behavioral therapy and pharmacotherapy of agoraphobia.
Topics: Agoraphobia; Behavior Therapy; Combined Modality Therapy; Desensitization, Psychologic; Follow-Up St | 1993 |
Clinical issues in the long-term treatment of panic disorder.
Topics: Age Factors; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Child; Cognitive B | 1996 |
Long-term outcome of panic disorder treatment. A review of the literature.
Topics: Agoraphobia; Combined Modality Therapy; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Psych | 1996 |
Rational treatment of panic disorder with antidepressants.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Comorbidity; Dose-Response | 1998 |
A review of the psychopharmacology of panic disorder: individual differences and non specific factors.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Combined Modality Therapy; Humans; Imipramine; Panic; Ph | 1991 |
Treatment of panic and agoraphobia. An integrative review.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Bibliographies as Topic; Clinical Tria | 1990 |
Differential effects of imipramine and behavior therapy on panic disorder with agoraphobia.
Topics: Agoraphobia; Behavior Therapy; Fear; Humans; Imipramine; Mental Disorders; Panic; Phobic Disorders | 1989 |
Agoraphobia.
Topics: Agoraphobia; Alprazolam; Behavior Therapy; Humans; Imipramine; Phobic Disorders | 1988 |
Update on the treatment of panic attacks.
Topics: Agoraphobia; Antidepressive Agents; Fear; Humans; Imipramine; Monoamine Oxidase Inhibitors; Panic; P | 1988 |
Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorders: a review.
Topics: Agoraphobia; Antidepressive Agents; Fear; Habituation, Psychophysiologic; Humans; Imipramine; Obsess | 1988 |
A model of panic and agoraphobic development.
Topics: Agoraphobia; Anxiety Disorders; Autonomic Nervous System; Fear; Humans; Imipramine; Panic; Phobic Di | 1987 |
Panic disorder: response to sodium lactate and treatment with antidepressants.
Topics: Agoraphobia; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Fear; Humans; Imipramine; | 1985 |
78 trials available for imipramine and Agoraphobia
| Article | Year |
|---|---|
Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Comb | 2008 |
Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder.
Topics: Adult; Agoraphobia; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow-Up Studi | 2008 |
Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Double-Blind Method; Drug Administration Sched | 1999 |
A 15-year follow-up study of patients with panic disorder.
Topics: Activities of Daily Living; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Sec | 2003 |
Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Dose-Response Re | 2005 |
Psychopathology of panic attacks in panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Cognition; Humans; I | 2006 |
Treatment of agoraphobia with group exposure in vivo and imipramine.
Topics: Adult; Agoraphobia; Behavior Therapy; Desensitization, Psychologic; Female; Group Processes; Humans; | 1980 |
Specific anxiety syndromes: current therapeutic options.
Topics: Agoraphobia; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepin | 1981 |
Treatment of phobias. II. Behavior therapy and supportive psychotherapy: are there any specific ingredients?
Topics: Agoraphobia; Behavior Therapy; Desensitization, Psychologic; Humans; Imipramine; Person-Centered Psy | 1983 |
Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework.
Topics: Adult; Agoraphobia; Behavior Therapy; Desensitization, Psychologic; Female; Follow-Up Studies; Human | 1983 |
Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo.
Topics: Adult; Agoraphobia; Ambulatory Care; Behavior Therapy; Clinical Trials as Topic; Female; Humans; Imi | 1983 |
Treatment of panic disorder with imipramine alone.
Topics: Adult; Agoraphobia; Anxiety Disorders; Attitude to Health; Clinical Trials as Topic; Fear; Female; H | 1984 |
Two-year follow-up of agoraphobics after exposure and imipramine.
Topics: Adult; Agoraphobia; Behavior Therapy; Female; Follow-Up Studies; Humans; Imipramine; Male; Phobic Di | 1984 |
Changes in the drug treatment of anxiety disorders.
Topics: Agoraphobia; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder | 1984 |
Relationship between separation anxiety and panic and agoraphobic disorders.
Topics: Adult; Agoraphobia; Anxiety Disorders; Anxiety, Separation; Child; Clinical Trials as Topic; Fear; F | 1984 |
Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.
Topics: Adult; Agoraphobia; Anxiety; Behavior Therapy; Combined Modality Therapy; Female; Humans; Imipramine | 1983 |
The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia.
Topics: Adult; Agoraphobia; Desipramine; Female; Humans; Imipramine; Male; Phobic Disorders | 1984 |
Anxiety: differential diagnosis and treatment from a biologic perspective.
Topics: Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Diagnosis, Differential; Diazepam; Double- | 1981 |
Current concepts in psychiatry. Panic attacks and phobias.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents; Anxiety Disorders; Behavior Therapy; Clinical | 1982 |
Panic disorder with or without concomitant depression 5 years after treatment: a prospective follow-up.
Topics: Adult; Agoraphobia; Combined Modality Therapy; Comorbidity; Depressive Disorder; Doxepin; Female; Fo | 1995 |
Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Topics: Adult; Agoraphobia; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm | 1995 |
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
Topics: Adolescent; Adult; Agoraphobia; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Panic Dis | 1995 |
Maintenance drug therapy of panic disorder.
Topics: Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imipramine; | 1993 |
Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
Topics: Adult; Agoraphobia; Analysis of Variance; Blood Pressure; Dose-Response Relationship, Drug; Double-B | 1994 |
Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Me | 1993 |
Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.
Topics: Adult; Agoraphobia; Appetite; Body Weight; Diazepam; Dietary Carbohydrates; Double-Blind Method; Fem | 1993 |
Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Doxepin; Follow-Up | 1995 |
Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Imip | 1995 |
A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Topics: Adult; Agoraphobia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluvoxamine; Huma | 1996 |
Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Doxepin | 1996 |
Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Blood Platelets; Down-Regulation; GTP-Binding | 1999 |
Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
Topics: Adult; Agoraphobia; Clinical Trials as Topic; Desensitization, Psychologic; Female; Humans; Imiprami | 1999 |
The use of the Panic and Agoraphobia Scale in a clinical trial.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Desensitization, Ps | 1998 |
A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents; Clomipramine; Demography; Female; Humans; Imipramin | 2000 |
The side effects burden of extended imipramine treatment of panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Blood Pressure; Female; Heart Rate; Humans; Im | 2000 |
2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Drug Administration Schedule; Female; Humans; Imipram | 2001 |
Emotion-focused psychotherapy for patients with panic disorder.
Topics: Adult; Agoraphobia; Cognitive Behavioral Therapy; Emotions; Female; Humans; Imipramine; Male; Middle | 2001 |
Specific side effects of long-term imipramine management of panic disorder.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Agoraphobia; Arousal; Dose-Response Relationship, Dr | 2002 |
Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distribution; | 2002 |
Comparison of short-term treatment regimens in phobic patients: a preliminary report.
Topics: Adult; Agoraphobia; Ambulatory Care; Behavior Therapy; Clinical Trials as Topic; Desensitization, Ps | 1976 |
Behavior therapy, supportive psychotherapy, imipramine, and phobias.
Topics: Adult; Agoraphobia; Behavior Therapy; Desensitization, Psychologic; Female; Follow-Up Studies; Human | 1978 |
Imipramine and phobia [proceedings].
Topics: Agoraphobia; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Imipramine; Male; Phobic Dis | 1977 |
Imipramine, behavior therapy, and phobia.
Topics: Agoraphobia; Behavior Therapy; Clinical Trials as Topic; Female; Humans; Imipramine; Male; Phobic Di | 1975 |
Treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorde | 1992 |
Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Blood Pressure; Body Weight; Double-Blind Method; Drug Administration Schedule; | 1992 |
Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Ambulatory Care; Double-Blind Method; Drug Administration Schedule; Female; Foll | 1992 |
Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Double-Blind Method; Fear; Female; Humans; Imipramine; Male | 1991 |
Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Female; | 1991 |
The structure of phobias in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; | 1991 |
Treatment of panic and agoraphobia. An integrative review.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Bibliographies as Topic; Clinical Tria | 1990 |
Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
Topics: Adult; Agoraphobia; Alprazolam; Analysis of Variance; Anxiety; Anxiety Disorders; Depression; Disabi | 1990 |
Drug treatment of panic disorder: early response to treatment as a predictor of final outcome.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Double-Blind Method; Female; Humans; Imi | 1990 |
Is buspirone effective for panic disorder?
Topics: Adult; Agoraphobia; Anxiety Disorders; Arousal; Buspirone; Double-Blind Method; Fear; Female; Follow | 1990 |
Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; beta-Endorphin; Clinical Trials as Topic; Double- | 1989 |
Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.
Topics: Adolescent; Adult; Aged; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Dose-Response Rel | 1989 |
Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone.
Topics: Adult; Agoraphobia; Brain; Buspirone; Clinical Trials as Topic; Double-Blind Method; Fear; Female; H | 1989 |
Combined pharmacological and behavioral treatment for agoraphobia.
Topics: Adult; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Desensitization, Psychologic; Human | 1985 |
A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Clinical Trials as To | 1986 |
Clinically significant improvement in agoraphobia research.
Topics: Adolescent; Adult; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Desensitization, Psycho | 1986 |
The placebo effect in agoraphobia.
Topics: Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Desensitization, Psychologic; Femal | 1987 |
Panic and avoidance in agoraphobia. Application of path analysis to treatment studies.
Topics: Adult; Agoraphobia; Anxiety Disorders; Behavior Therapy; Clinical Trials as Topic; Combined Modality | 1987 |
Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo.
Topics: Adult; Agoraphobia; Clinical Trials as Topic; Double-Blind Method; Fear; Female; Humans; Imipramine; | 1986 |
The relationship between panic, phobic and anticipatory anxiety in agoraphobia.
Topics: Adolescent; Adult; Agoraphobia; Clinical Trials as Topic; Fear; Female; Humans; Imipramine; Male; Mi | 1988 |
Overview of the Cross-National Collaborative Panic Study.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Fear; Goals; Humans; Imipramin | 1988 |
Initial depression and response to imipramine in agoraphobia.
Topics: Agoraphobia; Clinical Trials as Topic; Depression; Depressive Disorder; Dose-Response Relationship, | 1987 |
A naturalistic study of imipramine in panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Drug Administration Schedule; Fear; | 1987 |
Agoraphobics 5 years after imipramine and exposure. Outcome and predictors.
Topics: Adult; Agoraphobia; Behavior Therapy; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; I | 1987 |
Autonomic changes after treatment of agoraphobia with panic attacks.
Topics: Adult; Agoraphobia; Arousal; Behavior Therapy; Combined Modality Therapy; Fear; Humans; Imipramine; | 1988 |
Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.
Topics: Adult; Agoraphobia; Anxiety Disorders; Chlordiazepoxide; Clinical Trials as Topic; Double-Blind Meth | 1986 |
Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine.
Topics: Adult; Agoraphobia; Anxiety Disorders; Behavior Therapy; Chronic Disease; Clinical Trials as Topic; | 1986 |
Immunological response to stress in agoraphobia and panic attacks.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Fear; | 1986 |
Two-year follow-up of exposure and imipramine treatment of agoraphobia.
Topics: Agoraphobia; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Depressive Disor | 1986 |
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Fear; Humans; Imipramine; Pani | 1986 |
Imipramine in the treatment of panic disorder and its complications.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Anxiety Disorders; Behavior Therapy; Clinical Trials | 1985 |
Lactate vulnerability of remitted panic patients.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; D | 1985 |
Imipramine in the treatment of agoraphobia: dose-response relationships.
Topics: Agoraphobia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug A | 1985 |
Psychophysiological outcome of behavioral and pharmacological treatments of agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Behavior Therapy; Female; Heart Rate; Humans; Imipramine; Impl | 1985 |
49 other studies available for imipramine and Agoraphobia
| Article | Year |
|---|---|
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modalit | 2009 |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Chronic Disease; Dizziness; Female | 2011 |
Differential treatment of phobias: use of imipramine for panic attacks.
Topics: Adult; Agoraphobia; Desensitization, Psychologic; Fear; Female; Humans; Imipramine; Male; Panic; Pho | 1983 |
Clinical response to clonidine and imipramine, and platelet alpha 2-adrenoreceptors in a case of agoraphobia with panic attacks.
Topics: Adult; Agoraphobia; Blood Platelets; Clonidine; Drug Therapy, Combination; Fear; Humans; Imipramine; | 1982 |
Prognostic utility of Locus of Control in treatment of agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Female; Humans; Imipramine; Implosive Therapy; Internal-Extern | 1983 |
Panic attacks in phobia treatment studies.
Topics: Agoraphobia; Fear; Humans; Imipramine; Panic; Phobic Disorders | 1983 |
Imipramine with or without cognitive-behavior therapy in the treatment of an agoraphobic.
Topics: Agoraphobia; Behavior Therapy; Cognition; Combined Modality Therapy; Humans; Imipramine; Male; Middl | 1983 |
Agoraphobia: a multimodal treatment approach.
Topics: Adult; Agoraphobia; Combined Modality Therapy; Female; Humans; Imipramine; Marital Therapy; Panic; P | 1984 |
The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia.
Topics: Agoraphobia; Desipramine; Humans; Imipramine; Phobic Disorders | 1984 |
Lactate provocation of panic attacks. I. Clinical and behavioral findings.
Topics: Adult; Agoraphobia; Anxiety Disorders; Clonidine; Desipramine; Fear; Female; Humans; Imipramine; Lac | 1984 |
Treatment of agoraphobia and panic attacks.
Topics: Agoraphobia; Anxiety Disorders; Behavior Therapy; Double-Blind Method; Fear; Humans; Imipramine; Pan | 1983 |
Agoraphobia: the 'what if' syndrome.
Topics: Adolescent; Adult; Agoraphobia; Female; Humans; Imipramine; Male; Phenelzine; Phobic Disorders; Psyc | 1981 |
The dexamethasone suppression test in panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Anxiety Disorders; Depressive Disorder; Dexamethasone; Diagnosis, Differential; | 1982 |
Patterns of psychophysiological change in the treatment of agoraphobia.
Topics: Adult; Agoraphobia; Arousal; Female; Humans; Imipramine; Implosive Therapy; Phobic Disorders | 1982 |
Agoraphobia and imipramine withdrawal?
Topics: Agoraphobia; Female; Humans; Imipramine; Infant, Newborn; Infant, Newborn, Diseases; Phobic Disorder | 1982 |
Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Diazepam; Double-Blind Method; Humans; | 1982 |
Current drug therapy for agoraphobia.
Topics: Adult; Agoraphobia; Double-Blind Method; Evaluation Studies as Topic; Female; Humans; Imipramine; Ph | 1981 |
[Integrated treatment strategies in panic disorder with agoraphobia and depressive disorder].
Topics: Adult; Agoraphobia; Behavior Therapy; Child; Combined Modality Therapy; Depressive Disorder; Dose-Re | 1995 |
[Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy].
Topics: Adult; Agoraphobia; Antidepressive Agents; Behavior Therapy; Benzamides; Combined Modality Therapy; | 1995 |
Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.
Topics: Adult; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Desensitization, Psychologic; Femal | 1993 |
Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment.
Topics: Adult; Agoraphobia; Anxiety Disorders; Binding Sites; Blood Platelets; Depressive Disorder; Humans; | 1996 |
The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Topics: Agoraphobia; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Arousal; Dose-Response Relations | 1997 |
Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Antidepressive Agents, Tricyclic; Female; Follow-Up Studies; H | 1998 |
[Coincidence of schizophrenia and panic disorder].
Topics: Agoraphobia; Cognitive Behavioral Therapy; Combined Modality Therapy; Dibenzothiepins; Female; Human | 1999 |
Case 1. Assessment and treatment of phobic anxiety.
Topics: Adjustment Disorders; Adult; Agoraphobia; Anxiety; Behavior Therapy; Diagnosis, Differential; Female | 1979 |
Effect of imipramine treatment on heart rate variability measures.
Topics: Adult; Agoraphobia; Arousal; Blood Pressure; Depressive Disorder; Electrocardiography; Female; Heart | 1992 |
A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
Topics: Agoraphobia; Alprazolam; Female; Humans; Imipramine; Male; Panic Disorder; Psychiatric Status Rating | 1992 |
Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients.
Topics: Adult; Agoraphobia; Clomipramine; Dexamethasone; Diagnosis, Differential; Female; Humans; Hydrocorti | 1991 |
The effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients.
Topics: Adult; Agoraphobia; Ambulatory Care; Anxiety Disorders; Carbon Dioxide; Female; Humans; Imipramine; | 1990 |
Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia.
Topics: Adolescent; Adult; Agoraphobia; Anxiety Disorders; Behavior Therapy; Combined Modality Therapy; Fear | 1990 |
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.
Topics: Adult; Agoraphobia; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Anxiety Disorders; Ap | 1989 |
Three cases of panic disorder with agoraphobia in children.
Topics: Adolescent; Agoraphobia; Alprazolam; Child; Fear; Female; Humans; Imipramine; Male; Panic; Phobic Di | 1989 |
Fluoxetine in panic disorder patients with imipramine-associated weight gain.
Topics: Adult; Agoraphobia; Depressive Disorder; Fear; Female; Fluoxetine; Humans; Imipramine; Middle Aged; | 1989 |
Behavioural and combined therapy in panic states.
Topics: Agoraphobia; Anxiety Disorders; Behavior Therapy; Cognition; Combined Modality Therapy; Desensitizat | 1987 |
Drug therapy for agoraphobia.
Topics: Agoraphobia; Desensitization, Psychologic; Evaluation Studies as Topic; Humans; Imipramine; Phobic D | 1988 |
The cause and treatment of agoraphobia.
Topics: Agoraphobia; Anxiety Disorders; Arousal; Desensitization, Psychologic; Humans; Imipramine; Life Chan | 1988 |
Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment.
Topics: Adult; Agoraphobia; Anxiety Disorders; Blood Pressure; Brain; Female; Humans; Imipramine; Male; Meth | 1985 |
Tritiated imipramine binding to platelets is decreased in patients with agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Bipolar Disorder; Blood Platelets; Carrier Proteins; Depressiv | 1985 |
Differential 3H-imipramine platelet binding in patients with panic disorder and depression.
Topics: Agoraphobia; Blood Platelets; Carrier Proteins; Depressive Disorder; Fear; Humans; Imipramine; Kinet | 1987 |
Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Dose-Response Rel | 1988 |
Antipanic drug effects during lactate infusion in lactate-refractory panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Desipramine; Fear; Female; Fluoxetine; Humans; Imipramine | 1987 |
Imipramine treatment of agoraphobia.
Topics: Agoraphobia; Double-Blind Method; Humans; Imipramine; Phobic Disorders; Research Design | 1987 |
Anxiety reconceptualized. Gleaning from pharmacological dissection--early experience with imipramine and anxiety.
Topics: Agoraphobia; Anxiety Disorders; Anxiety, Separation; Arousal; Behavior Therapy; Combined Modality Th | 1987 |
Agoraphobia.
Topics: Agoraphobia; Alprazolam; Anxiety, Separation; Behavior Therapy; Combined Modality Therapy; Humans; I | 1987 |
Panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Animals; Anxiety Disorders; Behavior Therapy; Benzodiazepines; Diagnosis, Differ | 1986 |
Imipramine binding in agoraphobia.
Topics: Agoraphobia; Depressive Disorder; Humans; Imipramine; Phobic Disorders | 1986 |
Successful use of clonazepam in patients with treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clonazepam; D | 1986 |
Platelet [3H]imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks.
Topics: Adult; Agoraphobia; Anxiety Disorders; Blood Platelets; Female; Humans; Imipramine; Kinetics; Male; | 1987 |
Depression, agoraphobia, and the DST.
Topics: Agoraphobia; Depressive Disorder; Dexamethasone; Female; Humans; Imipramine; Middle Aged; Phobic Dis | 1985 |